Latest developments, partnerships and scientific breakthroughs
leadXpro AG and the University of Zurich (UZH) collaborate to generate sybodies as molecular discovery tools, therapeutic lead compounds and diagnostic reagents against disease-relevant membrane protein targets.
leadXpro AG and InterAx Biotech AG, join forces to discover and optimize new drug lead molecules targeting G-protein coupled receptors.
The Swiss Commission for Technology and Innovation CTI awards leadXpro the CTI startup label.
BASF and leadXpro AG will join forces to collaborate on the structure-based discovery of new active ingredients by employing single particle cryo-electron microscopy.
leadXpro AG scientists explore the utility of cutting-edge X-ray technologies for the discovery of new therapeutics.
Creoptix and leadXpro AG announce the selection of the Creoptix WAVE technology by leadXpro to strengthen its capabilities for drug discovery aimed at identifying and optimizing drug candidates directed against challenging membrane protein drug targets.
leadXpro and AXXAM announce the collaboration for the discovery of small molecular ligands to a novel inflammation related GPCR target.
Tripling its physical footprint and with a new funding round secured, leadXpro AG is well-prepared for further development.
